The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Elsewhere, a Phase III trial in the US has been planned for BioVie’s Triolex (bezisterim), which is an inhibitor of ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expres ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.

The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently ...